ClinicalTrials.gg
RecruitingNCT05407987FORGE IIUpdated Oct 28, 2026

Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery)

A Phase 3 interventional study of Ferric derisomaltose and Placebo in Gynecologic Cancer, Anemia and Iron-deficiency, sponsored by AHS Cancer Control Alberta. Recruiting at 1 site in Canada. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Primary conditionAnemia, Iron-DeficiencyRegistry: AnemiaReclassifiedWhy we changed it
Registry
Anemia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Anemia, Iron-Deficiency
Why
  1. The study's title name Anemia, Iron-Deficiency, a narrower term within Anemia.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by AHS Cancer Control Alberta · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.
Updated Oct 28, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency — 8 open to participants now, 9 under way, 4 of them phase 3. iron isomaltoside 1000 · Anemia, Iron-Deficiency.

Planned enrollment
23rd of 32
82 · median 121
Started
2025
with 2 others
Phase 3
18 of 32
4 open now
Registered
26th of 32
by date
Lead sponsor
1 of 32
AHS Cancer Control Alberta

Among the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency, this one is the 23rd largest by planned enrollment, is one of 3 that started in 2025, is one of 18 in phase 3, and was the 26th registered.

Anemia, Iron-Deficiency

602 studies on the registry are indexed under Anemia, Iron-Deficiency; 93 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

8 of the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency are open now, in 6 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About iron isomaltoside 1000

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 53 Anemia, Iron-Deficiency studies recruiting now, 19 (36%) set no upper age limit and 30 (57%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency, or all of them as a file.
02

Study summary

Iron deficiency has been reported in approximately 35% of patients with a gynecologic malignancy. Blood transfusions are known to be immunosuppressive and carry immediate and long-term risks. Pre-operative blood transfusion in gynecologic oncology patients is associated with higher rates of surgical site infection, length of stay, composite morbidity, cancer recurrence, and mortality. Pre-operative intravenous iron formulations have been shown in benign gynecology and other surgical specialities to increase pre-operative hemoglobin and decrease post-operative transfusion rates.

This is a randomized double-blinded clinical trial evaluating the effects of treating patients undergoing gynecologic oncology surgery with intravenous ferric derisomaltose to correct pre-operative iron-deficiency anemia.

The study aims to assess the effectiveness of preoperative ferric derisomaltose/iron isomaltoside compared to placebo in correcting preoperative hemoglobin in patients undergoing surgery for gynecologic malignancy.

03

Conditions studied

  • Gynecologic Cancer
  • Anemia
  • Iron-deficiency

Browse trials for

04

In context

Anemia, Iron-Deficiency Reclassified

602 studies on the registry are indexed under Anemia, Iron-Deficiency; 93 are open to participants now.

This study's planned enrollment of 82 is below the median of 100 across 461 interventional studies indexed under Anemia, Iron-Deficiency.

Browse Anemia, Iron-Deficiency studies →

Lead sponsor

AHS Cancer Control Alberta is the lead sponsor of 187 studies on the registry; 24 are open to participants now.

Compared within Anemia, Iron-Deficiency, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anemia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed written prior to initiation of any study specific activities/procedures.
  2. Age ≥ 18 years old.
  3. Patients undergoing elective major surgery on the gynecologic oncology service with the following criteria will be considered for inclusion:

    1. The indication for the operation may be for suspected or proven gynecologic .
    2. Major surgery is defined as an operation of a duration of 1 hour or greater, with an Aletti complexity score of at least 1.
    3. The expected time from recruitment to surgery is 28-90 days.
  4. Screening less than 120 g/L and transferrin saturation (TSAT) \<20%.
  5. Randomization and administration of study infusion a minimum of 21 days and maximum 90 days before planned operation.
  6. Negative pregnancy test for women of (WOCBP) (within 7 days prior to treatment).
  7. WOCBP must adhere to the requirement from screening throughout the study period until 6 weeks post treatment.
  8. Laboratory data used for determination of eligibility (Hemoglobin and Transferrin saturation) at the baseline visit must not be older than 4 weeks.

Exclusion criteria

Exclusion Criteria:

  1. Known history of acquired iron overload, or family history of haemochromatosis or thalassemia, or TSAT >50%.
  2. Known alternative cause for anemia (e.g., B12 or folate deficiency, or haemoglobinopathy).
  3. Known to Ferric derisomaltose/iron isomaltoside (Monoferric®) or its .
  4. Temperature >38C or patient on non-prophylactic antibiotics.
  5. Known chronic liver disease or active hepatitis.
  6. Received erythropoietin or IV iron therapy within previous 12 weeks prior to planned study drug treatment.
  7. (ALT) or aspartate transaminase (AST) above three times the (ULN) range.
  8. therapy (for solid organ transplant), or renal dialysis (current, or planned within next 12 months following treatment with study drug or placebo).
  9. Unfit for elective surgery.
  10. Pregnancy or lactation.

1. Unable to fully comprehend and/or perform study procedures and patients with psychiatric illness/social situations/substance abuse that would limit compliance with study requirements.

11. Cervical cancer with a clinical stage of 2A or greater.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
82 participants (estimated)

Study arms

  • Experimental
    Iron Therapy Arm

    500 or 1000mg of IV Ferric Derisomaltose in 100mL normal saline will be administered intravenously over 1 hour. Participants with bodyweight \<50kg will receive 500mg, participants with bodyweight \>50kg will receive 1000mg to ensure no patient exceeds the manufacturer's recommended dose of 20mg/kg bodyweight.

    Drug: Ferric derisomaltose

  • Placebo comparator
    Placebo Arm

    100mL of normal saline will be administered intravenously over 1 hour between 21 and 90 days preceding surgical intervention.

    Drug: Placebo

Interventions

  • DrugIron isomaltoside 1000Studies of Iron isomaltoside 1000Iron isomaltoside 1000 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Ferric Derisomaltose is a solution based iron supplement provided in 100 mg elemental iron/mL. Patients randomized to Iron Therapy Arm will with a bodyweight \<50kg will receive 500mg of Ferric Derisomaltose, and patients with a bodyweight \>50kg will receive 1000mg of Ferric Derisomaltose, to ensure no patient exceeds the manufacturer's recommended dose of 20mg/kg. Patients will receive a single infusion between 21 and 90 days preceding surgical intervention.

    Also known as: MONOFERRIC

  • DrugPlacebo

    Patients randomized to the Placebo arm will receive 100mg of normal saline over 1 hour.

07

What researchers measure

Primary outcomes

  1. Mean preoperative haemoglobin concentration

    To determine the effect of IV iron supplementation provided at least 21 days prior to surgery for gynecologic malignancy on mean preoperative haemoglobin concentration (in g/L)in patients with iron deficiency anemia compared to those patients without preoperative IV iron supplementation.

    Time frame: Haemoglobin concentration will be measured at baseline and 3 days prior to surgery after treatment with Ferric Derisomaltose

Secondary outcomes

  1. Mean haemoglobin concentration at the time of surgery

    The effect of IV iron supplementation provided prior to surgery for gynecologic malignancy on mean haemoglobin concentration (in g/L) at the time of surgery.

    Time frame: Haemoglobin concentration will be measured at baseline and at the time of surgery after treatment with Ferric Derisomaltose

  2. Mean postoperative haemoglobin concentration

    The effect of IV iron supplementation provided prior to surgery for gynecologic malignancy on mean hemoglobin concentration after the completion of surgery which will be assessed by measuring blood hemoglobin levels

    Time frame: Haemoglobin concentration will be measured at 28 and 60 days after surgery

  3. Assessment of the requirement of postoperative blood transfusion

    The number of participants requiring blood transfusion after completion of gynecologic surgery. A blood transfusion event is defined as receiving any volume of one unit or more than one unit of packed red cells or whole blood.

    Time frame: Day 0 to 28 days following surgery

  4. Mean number of blood transfusions

    The mean number of blood transfusion (total number of units of packed red blood cells transfused ) after completion of gynecologic surgery

    Time frame: Day 0 to 28 days following surgery

  5. Postoperative Quality of Recovery(QoR)-15 questionnaire score

    Quality of life will be evaluated using Quality of Recovery(QoR)-15 questionnaire score at postoperative day 1 compared to baseline (minimum value : 0, maximum value : 150, the higher the score, the better the result)

    Time frame: Post-operation day 1 (24 hours ± 12 hours following surgery)

  6. Mean Change in the Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scores

    The FACT-An questionnaire is a 47-item, cancer specific questionnaire consisting of a core 27 items measuring 4 general domains physical well being (PWG), social/family (SWB), emotional well being (EWB) and Functional Well-Being (FWB) and an additional 20-item anemia questionnaire that measures fatigue associated items and 7 non-fatigue items. The scales are formatted on 1 to 4 pages for self-administration using a 5-point Likert rating scale (0 = Not at all; 1 = A little bit; 2 = Somewhat; 3 = Quite a Bit and 4 = Very much). Also, general health related quality of life (HRQoL), the FACT-An measures the impact of fatigue and other anemia-related symptoms on patient functioning and is used to assess the effect of treatments in various therapeutic areas, including MDS.

    Time frame: Baseline to 0-3 days prior to surgery and at 23-33 days postoperative

  7. Mean Change in Quality of life measured with the EQ5D5L (European Quality of Life Five Dimension) scores

    Health-related quality of life will be measured using the EuroQol Five Dimensions (EQ-5D). The EQ-5D-5L is a valid extension of the 3-level questionnaire. It can be defined as a standardized non-disease specific value-based instrument to describe and value health-related quality of life. The instrument consists of two components: the EQ-5D descriptive system and the EQ visual analogue scale (EQ-VAS).The first part consists of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five response categories (no problems, slight problems, moderate problems, severe problems, and extreme problems), from which a single EQ-5D index score can be calculated ranging from 0 (dead) to 1 (perfect health). The EQ-VAS measures one's self-perceived health today on a vertical scale from 0 (worst imaginable health) to 100 (best imaginable health) on which participants have to indicate their current health.

    Time frame: Baseline to 0-3 days prior to surgery and at 23-33 days postoperative

  8. Mean Change in Quality of life measured with the SF-36 scores

    The SF-36 is a 36-item survey of health and well-being. The scale consists of eight domains: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning and mental health. Minimum Value: 0 (worst outcome) Maximum Value: 100 (best outcome)

    Time frame: Baseline to 0-3 days prior to surgery and at 23-33 days postoperative

  9. Clinical surgical site infection

    Rate of participants presenting with clinical surgical site infection will be measured post-operation.

    Time frame: within 28 days following surgery

  10. Clinical surgical complications

    Proportion of participants experiencing any complication post-operatively

    Time frame: within 28 days following surgery

  11. Postoperative length of hospital stay

    Mean and median length of stay (in days) in hospital following surgery

    Time frame: From Surgery date up to 60 days post surgery

  12. Rate of hospital readmission

    Proportion of participants requiring re-admission to hospital following surgery after initial discharge

    Time frame: from discharge date to 28 days post surgery

08

Study locations

1 of 1 sites recruiting
09

References and documents

Publications

  • Bisch SP, Woo L, Ljungqvist O, Nelson G. Ferric derisomaltose and Outcomes in the Recovery of Gynecologic oncology: ERAS (Enhanced Recovery After Surgery) (FORGE) - a protocol for a pilot randomised double-blinded parallel-group placebo-controlled study of the feasibility and efficacy of intravenous ferric derisomaltose to correct preoperative iron-deficiency anaemia in patients undergoing gynaecological oncology surgery. BMJ Open. 2023 Nov 9;13(11):e074649. doi: 10.1136/bmjopen-2023-074649. PubMed 37945297 ↗

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Dec 2027, 32 months after the start.

Of 49 phase 3 interventional studies under Anemia, Iron-Deficiency, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's planned 32 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Dec 2026 → Dec 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2022
First posted
Jun 7, 2022
StartActual
Apr 8, 2025
Primary completionEst.
Dec 30, 2027was Dec 2026
CompletionEst.
Dec 30, 2027was Dec 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 30, 2026→Dec 30, 2027
Oct 28, 2026
Study completion
Dec 30, 2026→Dec 30, 2027
Oct 28, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 37945297 ↗
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 37945297 ↗
    Primary completion Dec 30, 2026→Dec 30, 2027
    Study completion Dec 30, 2026→Dec 30, 2027
    + 3 other changes: index terms, verification date and criteria formatting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05407987
Responsible party
Sponsor
First posted
Jun 7, 2022
Start date
Apr 8, 2025
Primary completion
Dec 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Oct 28, 2026

Study contacts

Steven Bisch, MD
Contact
Steven.Bisch@ahs.ca
403-521-3721
Michelle Kan
Contact
michelle.kan@ahs.ca

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iron isomaltoside 1000

Start the discussion